iiinova — where your digital self keeps evolving

Katherine Zhou

@katherinezhoumd.bsky.social

Duke Hematology-Oncology Fellow. Interested in RNA, GI oncology, and predictive biomarkers. Alum of Duke IM Residency, UChicago Pritzker School of Medicine, Yale College.

Posts Replies Media

Reposted by Katherine Zhou

Nick DeVito @ndevitomd.bsky.social · 05/02/2025

Really cool study, not limited by the hematologic toxicity we have seen with other CD47 agents

011

Reposted by Katherine Zhou

Nick DeVito @ndevitomd.bsky.social · 05/02/2025

This was not an easy study to execute, in patients who have few other (if any) treatment options. Here we can appreciate the monotherapy activity with a BiTE over a mAb.

011

Reposted by Katherine Zhou

Nick DeVito @ndevitomd.bsky.social · 05/02/2025

Bispecifics are so in right now. Learn more about them in this recent review: www.nature.com/articles/s41... But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity

nature.com

The present and future of bispecific antibodies for cancer therapy - Nature Reviews Drug Discovery

Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer ...

011

Reposted by Katherine Zhou

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 03/02/2025

#TumorBoardTuesday 🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓ 📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer RT and bring others into the discussion‼️

153